These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 24507802)

  • 1. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.
    Gill H; Hwang YY; Chan TS; Pang AW; Leung AY; Tse E; Kwong YL
    J Clin Virol; 2014 Apr; 59(4):255-8. PubMed ID: 24507802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.
    Scheinberg P; Fischer SH; Li L; Nunez O; Wu CO; Sloand EM; Cohen JI; Young NS; John Barrett A
    Blood; 2007 Apr; 109(8):3219-24. PubMed ID: 17148582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
    Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
    Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
    O'Brien S; Ravandi F; Riehl T; Wierda W; Huang X; Tarrand J; O'Neal B; Kantarjian H; Keating M
    Blood; 2008 Feb; 111(4):1816-9. PubMed ID: 18039954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L; Linde A; Falk KI
    Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.
    Cameron BM; Kennedy SE; Rawlinson WD; Mackie FE
    Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27704725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation.
    Höcker B; Böhm S; Fickenscher H; Küsters U; Schnitzler P; Pohl M; John U; Kemper MJ; Fehrenbach H; Wigger M; Holder M; Schröder M; Feneberg R; Köpf-Shakib S; Tönshoff B
    Transpl Int; 2012 Jul; 25(7):723-31. PubMed ID: 22533698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.
    Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J
    J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma.
    Bossolasco S; Falk KI; Ponzoni M; Ceserani N; Crippa F; Lazzarin A; Linde A; Cinque P
    Clin Infect Dis; 2006 Feb; 42(4):e21-5. PubMed ID: 16421782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus.
    Hierro L; Díez-Dorado R; Díaz C; De la Vega A; Frauca E; Camarena C; Muñoz-Bartolo G; González de Zárate A; López Santamaría M; Jara P
    Liver Transpl; 2008 Aug; 14(8):1185-93. PubMed ID: 18668670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report.
    Venturi C; Bueno J; Gavalda J; Tórtola T; Pou L; Medina A; Codina G; Charco R; Pahissa A
    Transplant Proc; 2009 Apr; 41(3):1038-40. PubMed ID: 19376420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation.
    Verghese PS; Schmeling DO; Knight JA; Matas AJ; Balfour HH
    Transplantation; 2015 Jun; 99(6):1186-91. PubMed ID: 25489844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A therapeutic trial of valganciclovir in patients with uveitis and positive Epstein-Barr virus early antigen D IgG titers.
    Boonsopon S; Maghsoudlou A; Kombo NE; Foster CS
    Eur J Ophthalmol; 2016; 26(1):30-5. PubMed ID: 26350994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Reactivation of Cytomegalovirus and Epstein-Barr Virus in Patients with B Cell Lymphoma.
    Hatayama Y; Watanabe K; Ichikawa H; Kawamura K; Fukuda T; Motokura T
    Viral Immunol; 2023 Oct; 36(8):520-525. PubMed ID: 37440168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
    Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
    Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution.
    Annels NE; Kalpoe JS; Bredius RG; Claas EC; Kroes AC; Hislop AD; van Baarle D; Egeler RM; van Tol MJ; Lankester AC
    Clin Infect Dis; 2006 Jun; 42(12):1743-8. PubMed ID: 16705581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus encephalitis in solid organ transplantation.
    Lau JSY; Low ZM; Abbott I; Shochet L; Kanellis J; Kitching AR; Korman TM
    New Microbiol; 2017 Jul; 40(3):212-217. PubMed ID: 28513810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
    Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
    Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.